Radiofrequency Ablation of Renal Cell Carcinoma: Part 1, Indications, Results, and Role in Patient Management over a 6-Year Period and Ablation of 100 Tumors

Gervais, Debra A.; McGovern, Francis J.; Arellano, Ronald S.; McDougal, W. Scott; Müeller, Peter R.

doi:10.2214/ajr.185.1.01850064

Cited by 550 publications

(338 citation statements)

References 25 publications

Supporting

Mentioning

304

Contrasting

Unclassified

Order By: Relevance

“…All other reported adverse events (e.g., pain, nausea, fever, hemorrhage) were grade 1. The adverse events in this series were therefore comparable to those reported in previous larger series [8,9], in which the complication rates ranged from 8% to 13%. Although a transhepatic approach, which was reported to be safe for selected tumors [20], was selected for two sessions in the present study, it was not associated with adverse events.…”

Section: Discussionsupporting

confidence: 87%

“…In addition, the eGFR values before and "1 month after the procedure were 78. 8 23.0 mL/min/1.73 m 2 and 70. 2 21.9 mL/min/1.73 m 2 , respectively (p < 0.001; Table 2).…”

Section: Resultsmentioning

confidence: 98%

“…All of the tumors were progressive and were therefore expected to exceed a diameter of 3 cm in the future, especially when the young age of the patients (mean: 35.5 years) was considered. Additionally, once a tumor exceeds 3 cm in diameter, local control via RF ablation might become more challenging [8,9]. Therefore, we treated the tumors before they reached 3 cm in diameter.…”

Section: Discussionmentioning

confidence: 99%

“…Percutaneous image-guided radiofrequency (RF) ablation has been recently accepted as a treatment option for RCC [8][9][10] and has been described by many authors as a safe and effective procedure that is expected to preserve renal function [11,12]. Given the multifocal nature of VHL, affected patients with RCC often require repeated treatments.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Percutaneous CT-guided Radiofrequency Ablation for Renal Cell Carcinoma in von Hippel-Lindau Disease: Midterm Results

Gobara

Hiraki

Iguchi

et al. 2016

Interventional Radiology

View full text Add to dashboard Cite

Purpose: To evaluate the safety and midterm results of radiofrequency (RF) ablation for the treatment of renal cell carcinoma (RCC) in patients with von Hippel-Lindau (VHL) disease. Materials and methods: This study included 13 patients with VHL (8 women and 5 men; mean age: 35.5 years) and RCC. Each patient presented with 1-6 RCCs (mean: 2.4 1.7) without extrarenal metastasis. The mean tumor diameter was 18.0 5.0 mm. Transcatheter arterial embolization was performed for 5 (16.7%) of 31 tumors. All RF ablation procedures involved the percutaneous use of internally cooled RF electrodes under computed tomography fluoroscopic guidance. Adverse events were evaluated using the Common Terminology Criteria for Adverse Events, version 4.0, and pre-and post-treatment estimated glomerular filtration rates (eGFRs) were compared using paired t-tests. Local tumor progression, distant metastasis, and survival were also evaluated. Results: Twenty-three RF ablation sessions were technically successful. A grade 3 adverse event (hydronephrosis due to blood clotting, thus requiring ureteral stent placement) occurred in 1 (4%) of 23 sessions. The mean eGFR measured at !1 month after ablation was significantly lower than the mean eGFR before ablation (70.2 21.9 versus 78.8 23.0, p < 0.001). Local tumor progression was seen in 1 (3%) of 31 tumors. No patients died, required dialysis, or developed extra-renal metastases during a median 40-month follow-up. Conclusions: RF ablation for RCC is a safe, highly effective, and promising treatment option for patients with VHL disease.

show abstract

Section: Discussionsupporting

confidence: 87%

“…In addition, the eGFR values before and "1 month after the procedure were 78. 8 23.0 mL/min/1.73 m 2 and 70. 2 21.9 mL/min/1.73 m 2 , respectively (p < 0.001; Table 2).…”

Section: Resultsmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Percutaneous CT-guided Radiofrequency Ablation for Renal Cell Carcinoma in von Hippel-Lindau Disease: Midterm Results

Gobara

Hiraki

Iguchi

et al. 2016

Interventional Radiology

View full text Add to dashboard Cite

show abstract

“…In most cases, percutaneous RF ablation can be performed in patients under conscious sedation, by using medications similar to those used with any other interventional radiology procedure. In the clinical arena, RF ablation has been used for the treatment of various neoplasms, including metastases from a variety of primary tumors (4,5), such as hepatocellular carcinoma (HCC) (6,7), renal cell carcinoma (RCC) (8,9), non-small cell lung cancer (NSCLC) (10,11), and osteoid osteoma (12,13). In this article we review RF ablation techniques and their clinical implications.…”

mentioning

confidence: 99%

Radiofrequency ablation: technique and clinical applications

Tatlı

Tapan²,

Morrison³

et al. 2011

Diagn Interv Radiol

View full text Add to dashboard Cite

Radiofrequency ablation is the most commonly used percutaneous ablation technique and well-documented in the literature on focal therapies. It has become the image-guided ablation method of choice because of its efficacy, safety, and ease of use. Radiofrequency ablation has shown promise in treating selected solid tumors, particularly those involving the liver, kidneys, lungs, and the musculoskeletal system. It is a minimally invasive technique often used in inoperable patients with other comorbidities. Radiofrequency ablation requires a minimal hospital stay or can be performed on an outpatient basis. The aim of this article is to review radiofrequency ablation techniques and their clinical applications.

show abstract